Background. Peritoneal fibrosis is a serious complication of peritoneal dialysis (PD); however, the mechanisms are poorly understood. The endothelin system exhibits potent pro-fibrotic properties and is known to be stimulated in peritoneal fibrosis. Thus, our study aimed at elucidating the impact of the endothelin B (ETB) receptor on peritoneal membrane thickening by means of an ETB-deficient rat model (ETB −/− ) in experimental PD. Methods. Wild-type (WT) and ETB −/− rats were randomly allocated to four groups (each group n = 10): (i) WT Sham, (ii) WT PD, (iii) ETB −/− Sham and (iv) ETB −/− PD. All animals underwent surgical implantation of a port for intraperitoneal administration and 1 week of habituation to the procedure by administration of 2 ml of saline once daily. Afterwards, all animals were switched to 12 weeks of 15 ml of saline (Sham groups) or commercially available PD fluid containing 3.86% glucose (PD groups) administered twice daily. Afterwards, animals were sacrificed, and samples from visceral as well as parietal peritoneum were obtained. The samples were stained with Sirius-Red, and at 10 different sites per sample, peritoneal membrane thickness was measured using computer-aided histomorphometry devices.
PD. All animals underwent surgical implantation of a port for intraperitoneal administration and 1 week of habituation to the procedure by administration of 2 ml of saline once daily. Afterwards, all animals were switched to 12 weeks of 15 ml of saline (Sham groups) or commercially available PD fluid containing 3.86% glucose (PD groups) administered twice daily. Afterwards, animals were sacrificed, and samples from visceral as well as parietal peritoneum were obtained. The samples were stained with Sirius-Red, and at 10 different sites per sample, peritoneal membrane thickness was measured using computer-aided histomorphometry devices. Results. Mean peritoneal membrane thickness was increased by PD in both WT and ETB −/− rats versus respec-
Introduction
Peritoneal fibrosis is a common complication in patients with end-stage renal disease on peritoneal dialysis (PD) [1] . The pathophysiological mechanisms involved in the process are only partially known. However, endothelin-1 (ET-1) is a potent pro-inflammatory and pro-fibrotic mediator, as its major biological effects include the induction of mitogenesis of fibroblasts, smooth muscle cells and myocytes, activation of neutrophils and the induction of fibronectin as well as chemotaxis of fibroblasts [2] . It acts via two receptors: the endothelin A (ETA) and endothelin B (ETB) receptor [3, 4] .
Both receptors are involved in the mediation of inflammation [5] and fibrosis [6] . In fibrotic diseases, often a shift is observed from a normal ETA/ETB tissue distribution to a diseased distribution favouring the ETB receptor [7] [8] [9] . Apart from being the cause of tissue fibrosis, this shift can also be interpreted as a counter-regulatory mechanism as the ETB receptor acts as a clearance receptor for ET-1 [10] . Furthermore, the ETB receptor mediates the production of nitric oxide [11] which in turn downregulates ET-1 production.
Concerning the role of ET-1 in peritoneal fibrosis, we demonstrated earlier in a human study that, indeed, the peritoneal ET-1 release is stimulated with increasing dwell volume in PD [12] . In order to assess the impact of ET-1 in mediating peritoneal fibrosis, we performed a cell culture study with human mesothelial cells [13] . We demonstrated that under conditions of increasing osmolarity or fluid stress indeed ET-1 release and collagen I expression was increased in human mesothelial cells, whereas presence of a dual ET receptor antagonist inhibited those effects. However, as a dual ET receptor antagonist was used in this study, the contribution of each specific ET receptor to peritoneal scarring remained unclear. A recent study by Shimizu et al. [14] also using cultured human mesothelial cells indicated a role for the ETB receptor in fibrous matrix protein production. Thus, we designed the present study to assess the impact of the ETB receptor on peritoneal fibrosis in a rat model of PD.
Materials and methods

Study design
Animal studies were carried out in accordance with German law governing the use and care of laboratory animals. Animals were housed under standardized conditions and with water and food ad libitum. ETB receptor-deficient rats (ETB −/− ) and wild-type controls (WT) were kindly provided by M. Yanagisawa. As the complete knockout of the ETB receptor is lethal due to intestinal aganglionosis (Hirschsprung's disease), the model we used is a transgenically rescued spotting lethal rat which carries a naturally occurring deletion of the ETB receptor. In our model, this rat is rescued by a transgenic ETB receptor gene under control of a dopaminebeta-hydroxylase promoter allowing expression of the ETB receptor mostly in intestinal tissue in order to prevent aganglionosis [15] . As it has not yet been demonstrated that, in peritoneal tissue of this model the ETB receptor is absent, we performed real-time PCR (rt-PCR) in order to confirm the absence as described in previous studies [16] .
During the study, Wistar rats were randomly allocated to four groups (each group: n = 10):
All animals underwent surgical implantation of a port (ROP, Access Technologies, Illinois, US; Figure 1 ) for intraperitoneal application of PD fluid (PD groups) or saline (Sham groups) as follows: After animals were put in general anaesthesia, two incisions were made: First, incision was performed dorsally at the neck, and a pocket for the port was built. Second incision was made at the left side of the abdomen. Afterwards, from the dorsal neck incision to the abdominal incision, a subcutaneous tunnel was prepared. The port was put into the pocket at the neck, and the catheter was inserted through the tunnel to the abdominal incision where the peritoneum was opened, and the tip of the catheter was inserted into the peritoneal cavity. Afterwards, all incisions were closed with sutures. Afterwards, 1 week for habituation to the port management was given by administration of 2 ml saline once daily (Figure 1 ). After habituation, animals were switched to 12 weeks of 15 ml of saline (Sham groups) or commercially available PD fluid containing 3.86% glucose (PD groups) administered twice daily. Throughout the study, antibiotic prophylaxis was carried out using staphylex (2.5 mg/day) and gentamycin (0.04 mg/day). At study end, PD fluid was stored at −80°C. ET-1, fibronectin, vascular endothelial growth factor (VEGF) and transforming growth factor-beta (TGF-ß) were analysed later by the appropriate ELISAs provided by Immundiagnostics, Bensheim, Germany. Thereafter, blood was taken, the animals were sacrificed and tissue samples from visceral as well as parietal peritoneum were obtained. Tissue samples were stained with Masson's trichrome and at 10 randomly chosen sites per sample peritoneal membrane thickness was measured using a light microscope combined with a PowerMac and image processing software (ImageJ, shareware from the National Institute of health). 
Peritoneal membrane thickness
Statistical analysis
The data are expressed as means ± SEM. Data for the groups were compared using the Mann-Whitney U-test. Statistical significance was assumed with a value of P < 0.05.
Results
As our animal model is a rescued ETB receptor knockout model, which is not completely deficient of the ETB receptor (see Materials and methods), we performed rt-PCR on various tissues including the peritoneum in order to demonstrate the absence of the ETB receptor in the peritoneum (see Figure 2) .
Administration of PD fluid significantly increased peritoneal membrane thickness in WT and ETB −/− rats versus respective Sham controls, thus indicating that our experimental model indeed mimics the clinical phenotype observed in humans ( Figure 3A) . Table 1 provides the concentration of the fibrosis-related mediators in the dialysis fluid. TGF-ß was found in significant higher amounts in the dialysate of ETB-deficient rats. Dialysate concentration of VEGF was significantly lower in the ETB PD group compared to the Sham control of the same genotype.
The results of the quantification of peritoneal membrane thickness in our study are illustrated in Figure 3A ; for illustration of the microscopical sample see Figure 3B . No differences between both Sham-operated groups regardless of genotype were observed with respect to peritoneal membrane thickness.
Discussion
Peritoneal fibrosis is a frequent complication of PD. In very severe cases, it may lead to treatment failure with the necessity to switch to an alternative renal replacement modality, usually haemodialysis. It is generally accepted that the pathogenesis of peritoneal fibrosis is attributed to a variety of different factors often acting in concert, such as the combination of bioincompatible factors in the dialysate, including high glucose [17] , high osmolality [13] , advanced glycation products [18] , glucose degradation products [19] , uraemic inflammation [20] and acute peritonitis with inflammation [21] .
Peritoneal fibrosis is often related to the duration of PD and goes along with an impaired net ultrafiltration and membrane failure [20, 22] . We recently identified the endothelin system as a potential mediator of peritoneal fibrosis. In a clinical trial, we found that the dwell volume as well as the osmolarity of the peritoneal dialysate had a strong impact on peritoneal ET-1 release [12] . In a following cell culture study with human mesothelial cells [13] , we indeed found that a high dialysate fluid osmolarity as well as fluid shear stress were significant triggers for both peritoneal ET-1 release and collagen I RNA expression. The presence of a dual ET receptor antagonist inhibited these effects completely. As a next step to elucidate the pathophysiologic role of the endothelin system, the present in vivo study was designed. We switched from a cell culture study to a PD rat model in order to have a more reliable approach.
In our model, PD rat model administration of PD fluid significantly increased peritoneal membrane thickness in WT and ETB −/− rats versus respective Sham controls, thus indicating that our experimental model indeed mimics the clinical phenotype observed in humans. We found significantly higher TGF-ß concentrations in the dialysate of ETB-deficient rats under baseline conditions and also after induction of peritoneal fibrosis. This suggests that the local peritoneal TGF-ß synthesis might be at least partially controlled by the ETB receptor even under baseline conditions. The underlying molecular mechanisms need to be addressed in further studies. In this context, it is interesting that diabetic ETB-deficient rats develop pronounced kidney fibrosis and renal failure [23] . In contrast to diabetic nephropathy, elevated TGF-ß seems not to contribute to peritoneal fibrous-or is counteracted by other mechanisms.
It is known that ET-1 stimulates VEGF synthesis. This ET-1 effect on VEGF synthesis seems to be mediated by the ETA and ETB receptor [24] . A lack of ETB receptors thus may lead to a reduced VEGF synthesis. As in arthrosclerosis, there might also be a shift from ETA to high ETB receptor expression in peritoneal fibrosis (meaning that VEGF synthesis now depends mainly on the ETB receptor) explaining why particularly the VEGF concentrations are low in the ETB knockout rats with peritoneal fibrosis.
In any case, quantifying peritoneal membrane thickness after a PD treatment period of 12 weeks revealed no difference between both Sham-operated groups regardless of genotype with respect to peritoneal membrane thickness. We thus suggest that, in our PD rat model, there is no evidence for a role of the ETB receptor in mediating peritoneal membrane thickening. Our findings are in contradiction with the human mesothelial cell based study of Shimizu [14] who indicated a role for the ETB receptor in fibrous matrix protein production. The discrepancy may be due to the fact that the authors focused on fibronectin whereas other matrix proteins (i.e. collagens) might be more important in peritoneal scarring. In our trial, the lowest fibronectin values were detected in WT rats on PD. We further should keep in mind that cell culture studies are highly artificial compared to the in vivo situation. Based on our findings and the well-known pro-fibrotic actions of the ETA receptor [25, 26] , we suggest the ETA receptor as a potential pathway in endothelin-dependent peritoneal scarring and warrant further studies to clarify this point. In summary, our study demonstrates that PD increases peritoneal membrane thickness in our rat model, but deficiency of the ETB receptor has no detectable impact on this process. However, the role of the ETA receptor in peritoneal fibrosis is unknown and should be addressed in further studies.
